New KRAS-Targeting Drug for Advanced Solid Tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be pancreatic, lung (non-small cell), or colon cancer that has spread beyond the original site
- Your tumor must have a specific KRAS mutation (G12C, G12D, G12V, G12A, G12S, or G13D) confirmed by a biopsy or blood test
- You must have at least one measurable tumor visible on imaging scans
- You must be in good overall health—able to do light activities or be mostly confined to bed but not completely bedridden
- You must have received all standard cancer treatments available for your cancer type, unless your doctor explains why you cannot receive them
- You cannot have had any prior drugs that specifically target KRAS mutations
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This study tests an experimental drug (RX001) given directly into tumors for people with advanced lung cancer that has a KRAS mutation. It is a phase 1 trial, so the main goal is to check safety and find a good dose.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
This study tests a new treatment for people with advanced solid tumors that have a specific genetic change called KRAS G12V. The treatment is designed to help the immune system attack cancer cells with this mutation, and the study aims to see if it is safe and effective.
This trial tests two new drugs together for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The treatment may help shrink tumors or slow their growth.
This trial is testing a new drug called BG-85738, which may target cancer cells that have a specific change (mutation) in the RAS gene. The goal is to see if it is safe and works against advanced or spreading solid tumors.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.